Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phytocannabinoids for Chemotherapy-Induced Peripheral Neuropathy
NCT05672342Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol and delta-8-tetrahydrocannabinol in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by City of Hope. Primary endpoint: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale at 12 weeks. Planned start Jul 2024; status: withdrawn.
02
Drugs
cannabidioldelta-8-tetrahydrocannabinol
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05672342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672342.